Lineage Cell Therapeutics
Market cap $207M 253.0M shares (10-Q, Nov 9, 2026) × $0.820 close Nov 17, 2026
Most recent annual filing: 2026-03-05
- COR1 readout2026COR1 readout, 2026, notable
- OpRegen warrants corporate updateMay 21, 2028OpRegen warrants corporate update, May 21, 2028, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (13 active programs)
OPC1
- Spinal Cord Injury
- Undisclosed indication
ReSonance
ANP1- Auditory Neuropathy
- Sensorineural Hearing Loss
- Undisclosed indication
PNC1
RND1
- Undisclosed indication
ILT1
COR1
- Fuchs Endothelial Corneal Dystrophy
- Bullous Keratopathy
- Corneal Endothelial Disease
HUNT1
hNSC-01Technology platforms
AlloSCOPE
Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering platform enabling large-scale manufacture of allogeneic cell therapies from a single pluripotent cell line; supports differentiation across multiple programs including ophthalmology (OpRegen, COR1), spinal cord injury (OPC1), auditory neuropathy (ReSonance/ANP1), and islet cell therapy (ILT1); AlloSCOPE 5D variant targets higher-scale production with reduced manipulation via fully suspension-based bioreactor process.
Factor Bioscience Gene-Editing Platform · Factor Bioscience
Patented gene-editing platform used to engineer hypoimmune iPSC lines for cell and gene therapy candidates; Lineage holds exclusive option and license to develop edited hypoimmune cell lines into differentiated cell transplant product candidates across a wide range of diseases
Discontinued (1)
- VAC2 — Non-Small Cell Lung Cancer · Company determined it was no longer going to pursue the VAC2 program and ceased development; VAC platform abandoned as of June 30, 2025
Capital (as filed)
- Cash
- $26.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $18.7M Sep 30, 2026
- Operating cash flow
- −$5.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $45.2M cash, runway Q2 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (2)
- 2026-11-13 UPDATE: Lineage Cell Therapeutics (LCTX) - The Huntington’s Bolt-On and a Shorter Runway 🔒 Paid
- 2026-08-17 Lineage Cell Therapeutics (LCTX) — Scientific Deep Dive for OpRegen, OPC1, and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (2 calls)
Every verdict Biotech Distilled has published on Lineage Cell Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-08-17 Watch Lineage Cell Therapeutics (LCTX) — Scientific Deep Dive for OpRegen, OPC1, and Pipeline Products Biology has receipts and platform is productive, but Lineage owns roughly half the economics of a lead asset it does not control on a timeline it cannot influence; revisit on Roche's public disclosure of intent to advance OpRegen into a controlled multicenter Phase 2/3.
- 2026-11-13 Watch UPDATE: Lineage Cell Therapeutics (LCTX) - The Huntington's Bolt-On and a Shorter Runway HUNT1 acquisition adds cheap optionality but runway slipped a quarter to Q2 2028 and Lineage now has a second program whose trial timeline it doesn't control; the Roche OpRegen controlled-trial trigger remains the only event that re-rates the stock.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (19)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 8, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseLineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease→ BD updateSummary on the 8-K
- Nov 12, 2026ReleaseLineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: material agreement, acquisition / disposition, results of operations · EX-99.1→ BD updateLineage closed today's acquisition of NeuroAirmid Therapeutics, adding HUNT1 — a pluripotent stem cell-derived neural therapy already dosed in 6 Huntington's patients, backed by $28M in CIRM funding — to its pipeline for a modest ~$4.7M at close, plus up to $48M in success-based milestones. The deal reshapes the "bench-wearing-a-program-name" bear case I called out in the deep dive, while adding new financial obligations that bear watching alongside Q2 2028 runway guidance.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 5, 2026ReleaseLineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
- Oct 29, 2026ReleaseLineage Provides Update on ReSonance® Program for Hearing Loss
- Sep 8, 2026ReleaseLineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1
- Aug 6, 202610-QQuarterly report
- Jun 12, 20268-KCurrent report: shareholder vote, other events
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- Apr 29, 2026DEFA14AProxy soliciting material
- Apr 29, 2026DEF 14AProxy statement
- Mar 11, 2026S-3Shelf registration
- Mar 11, 20268-KCurrent report: other events
- Mar 11, 2026424B5Prospectus supplement (offering)
- Mar 5, 20268-KCurrent report: results of operations · EX-99.1
- Mar 5, 202610-KAnnual report
5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Jul 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 29, 2026ARSAnnual report to shareholders
- Mar 23, 2026EFFECTRegistration effective
- Mar 19, 2026CORRESPCORRESP
- Mar 16, 2026UPLOADUPLOAD